These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 1283117)

  • 21. Urodynamic effects of finasteride in the treatment of bladder outlet obstruction due to benign prostatic hyperplasia.
    Tammela TL; Kontturi MJ
    J Urol; 1993 Feb; 149(2):342-4. PubMed ID: 7678871
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of long term treatment with finasteride (MK-906), a 5-alpha reductase inhibitor, on circulating LH, FSH, prolactin and estradiol.
    Matzkin H; Chen J; Lewyshon O; Ayalon D; Braf Z
    Horm Metab Res; 1992 Oct; 24(10):498-9. PubMed ID: 1281461
    [No Abstract]   [Full Text] [Related]  

  • 23. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia.
    Bartsch G; Rittmaster RS; Klocker H
    Eur Urol; 2000 Apr; 37(4):367-80. PubMed ID: 10765065
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Finasteride: a 5 alpha-reductase inhibitor.
    Steiner JF
    Clin Pharm; 1993 Jan; 12(1):15-23. PubMed ID: 7679063
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multicenter, randomized, double-blind, placebo controlled study to investigate the effect of finasteride (MK-906) on stage D prostate cancer.
    Presti JC; Fair WR; Andriole G; Sogani PC; Seidmon EJ; Ferguson D; Ng J; Gormley GJ
    J Urol; 1992 Oct; 148(4):1201-4. PubMed ID: 1383574
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Finasteride for benign prostatic hyperplasia.
    Holdcroft C
    Nurse Pract; 1993 Mar; 18(3):57-8. PubMed ID: 7681553
    [No Abstract]   [Full Text] [Related]  

  • 27. Effects of the 5 alpha-reductase inhibitor finasteride on serum levels of gonadal, adrenal, and hypophyseal hormones and its clinical significance: a prospective clinical study.
    Uygur MC; Arik AI; Altuğ U; Erol D
    Steroids; 1998 Apr; 63(4):208-13. PubMed ID: 9589555
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of finasteride, a 5 alpha-reductase inhibitor on prostate tissue androgens and prostate-specific antigen.
    Geller J
    J Clin Endocrinol Metab; 1990 Dec; 71(6):1552-5. PubMed ID: 1699965
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor.
    Clark RV; Hermann DJ; Cunningham GR; Wilson TH; Morrill BB; Hobbs S
    J Clin Endocrinol Metab; 2004 May; 89(5):2179-84. PubMed ID: 15126539
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effect of finasteride on prostate-specific antigen in men with benign prostatic hyperplasia.
    Guess HA; Heyse JF; Gormley GJ
    Prostate; 1993; 22(1):31-7. PubMed ID: 7678930
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effect of 5alpha-reductase inhibition with dutasteride and finasteride on bone mineral density, serum lipoproteins, hemoglobin, prostate specific antigen and sexual function in healthy young men.
    Amory JK; Anawalt BD; Matsumoto AM; Page ST; Bremner WJ; Wang C; Swerdloff RS; Clark RV
    J Urol; 2008 Jun; 179(6):2333-8. PubMed ID: 18423697
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MK-386, an inhibitor of 5alpha-reductase type 1, reduces dihydrotestosterone concentrations in serum and sebum without affecting dihydrotestosterone concentrations in semen.
    Schwartz JI; Tanaka WK; Wang DZ; Ebel DL; Geissler LA; Dallob A; Hafkin B; Gertz BJ
    J Clin Endocrinol Metab; 1997 May; 82(5):1373-7. PubMed ID: 9141518
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Finasteride: the first 5 alpha-reductase inhibitor.
    Sudduth SL; Koronkowski MJ
    Pharmacotherapy; 1993; 13(4):309-25; discussion 325-9. PubMed ID: 7689728
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [5-alpha reductase inhibitor in prostatic adenoma?].
    Heinzl S
    Med Monatsschr Pharm; 1990 Dec; 13(12):382-4. PubMed ID: 1705307
    [No Abstract]   [Full Text] [Related]  

  • 35. Thoughts on finasteride for benign prostatic hyperplasia.
    Anand A
    Am Fam Physician; 1993 Sep; 48(4):582, 588. PubMed ID: 7691035
    [No Abstract]   [Full Text] [Related]  

  • 36. Androgen metabolism in men receiving finasteride before prostatectomy.
    Norman RW; Coakes KE; Wright AS; Rittmaster RS
    J Urol; 1993 Nov; 150(5 Pt 2):1736-9. PubMed ID: 7692110
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New medication for the treatment of benign prostatic hyperplasia.
    Miller CA
    Geriatr Nurs; 1993; 14(2):111-2. PubMed ID: 7681420
    [No Abstract]   [Full Text] [Related]  

  • 38. Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone.
    Amory JK; Watts NB; Easley KA; Sutton PR; Anawalt BD; Matsumoto AM; Bremner WJ; Tenover JL
    J Clin Endocrinol Metab; 2004 Feb; 89(2):503-10. PubMed ID: 14764753
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Magnetic resonance imaging of the efficacy of specific inhibition of 5 alpha-reductase in canine spontaneous benign prostatic hyperplasia.
    Cohen SM; Taber KH; Malatesta PF; Shpungin J; Berman C; Carlin JR; Werrmann JG; Prahalada S; Bryan RN; Cordes EH
    Magn Reson Med; 1991 Sep; 21(1):55-70. PubMed ID: 1719333
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The influence of finasteride on the volume of the peripheral and periurethral zones of the prostate in men with benign prostatic hyperplasia.
    Tempany CM; Partin AW; Zerhouni EA; Zinreich SJ; Walsh PC
    Prostate; 1993; 22(1):39-42. PubMed ID: 7678931
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.